Telix Pharmaceuticals delivers a sharp revenue lift in the second quarter, powered by rising demand for its prostate cancer imaging products. Group revenue climbs 21% year on year to USD247 million, up from USD204 million in the same period last year.
Growth comes largely from its Gozellix and Illuccix prostate imaging portfolio. Management positions the result as evidence that demand remains strong across its precision imaging offerings.
The business highlights commercial, regulatory and clinical progress across its Precision Medicine and Therapeutics divisions. Leadership points to recently achieved milestones that help underpin confidence in near-term revenue. Telix says it is currently performing in line with the upper end of its full-year revenue guidance range.
The company is directing more capital into research and development to support its pipeline.
Guidance now calls for full-year revenue and other income to exceed USD1 billion, moving toward the upper limit of its previously stated USD950 million to USD970 million outlook. Telix expects the current demand trajectory for its imaging products to continue through the rest of the year.
Increased R&D investment is aimed at converting current commercial momentum into a broader therapeutic and diagnostics platform.
